Dapoxetine

Dapoxetine is a selective serotonin reuptake inhibitor (SSRI) that was designed specifically for the treatment of premature ejaculation (PE). It is the only drug with regulatory approval for such treatment in many countries.

Pharmacodynamics

Dapoxetine is a serotonin transporter inhibitor. It inhibits the reuptake of serotonin, leading to increased serotonin concentrations. The increased serotonin concentrations in the post synaptic cleft results in the promotion of ejaculatory delay.

Pharmacokinetics

Dapoxetine is rapidly absorbed and eliminated, resulting in minimal accumulation and has dose-proportional pharmacokinetics, which are unaffected by multiple dosing.

Efficacy and safety

Clinical trials have shown dapoxetine to have a benefit in the treatment of premature ejaculation. In a report published in the British Journal of Urology based on data from the phase III trial, it was suggested that dapoxetine can be beneficial for men with PE.

Regulatory status

Dapoxetine is approved in many countries worldwide, including some in Europe, Asia, and South America. However, it is not yet approved in the United States.

See also

• Selective serotonin reuptake inhibitor
• Premature ejaculation

References

<references />

• 
  Dapoxetine
• 
  Dapoxetine synthesis